STA
COLL icon

Summit Trail Advisors’s Collegium Pharmaceutical COLL Stock Holding History

Summit Trail Advisors’s Portfolio COLL Stock Details COLL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-6,913
Closed -$102K – 146
2018
Q3 		$102K Buy
6,913
+2,945
+74% +$52.2K 0.02% 271
2018
Q2 		$95K Sell
3,968
-12,913
-76% -$318K 0.03% 221
2018
Q1 		$333K Buy
16,881
+2,552
+18% +$60.8K 0.06% 258
2017
Q4 		$345K Buy
+14,329
New +$205K 0.04% 290

Other funds holding COLL

Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
FM
Frazier Management Seattle, Washington $1.12M AUM 151.58% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
RSCM
Rock Springs Capital Management Baltimore, Maryland $1.7B AUM 93.03% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Summit Trail Advisors's COLL Position: Q4 2018 in Review

Summit Trail Advisors sold out of Collegium Pharmaceutical (COLL) in Q4 2018, closing a stake of 6,913 shares — an estimated $102K sold.

Summit Trail Advisors first reported a position in COLL in Q4 2017 and held it in 4 quarters. The position peaked at $345K in Q4 2017. 120 funds tracked by Wall St. Rank hold COLL as of Q4 2018.

  • Summit Trail Advisors reported no remaining Collegium Pharmaceutical position as of Q4 2018 after selling out during the quarter.
  • Summit Trail Advisors sold 6,913 Collegium Pharmaceutical shares in Q4 2018, an estimated $102K.
  • Summit Trail Advisors first reported a position in Collegium Pharmaceutical in Q4 2017 and held it in 4 quarters.
  • Summit Trail Advisors's Collegium Pharmaceutical position peaked at $345K in Q4 2017.
  • 120 funds tracked by Wall St. Rank held Collegium Pharmaceutical as of Q4 2018.

Based on Summit Trail Advisors's 13F filing for Q4 2018, filed 13 Feb 2019.